Related Experiment Videos
Hyperkalaemia induced by carbonic anhydrase inhibitor
1Renal Division, Hiratsuka Kyousai Hospital, Japan.
The British Journal of Ophthalmology
|March 1, 1991
Summary
Carbonic anhydrase inhibitors can cause hyperkalemia in patients with selective aldosterone deficiency, contrary to expectations of hypokalemia. This occurs due to metabolic acidosis-induced potassium shifts.
Area of Science:
- Nephrology
- Ophthalmology
- Endocrinology
Background:
- Carbonic anhydrase inhibitors are commonly used for glaucoma treatment.
- These drugs can cause metabolic acidosis and electrolyte imbalances.
- Aldosterone deficiency impairs renal potassium excretion.
Observation:
- An 81-year-old male patient with glaucoma developed hyperkalemic and hyperchloremic metabolic acidosis.
- The patient had pre-existing mild renal failure and confirmed selective aldosterone deficiency.
- He was undergoing treatment with a carbonic anhydrase inhibitor.
Findings:
- The patient's condition did not present with hypokalemia, which is a typical side effect.
- Selective aldosterone deficiency limited the kidneys' capacity for potassium secretion.
- Metabolic acidosis induced by the carbonic anhydrase inhibitor likely caused transcellular potassium movement, leading to hyperkalemia.
Implications:
- This case highlights a paradoxical effect of carbonic anhydrase inhibitors in patients with aldosterone deficiency.
- It underscores the importance of monitoring potassium levels in such patients.
- Understanding these electrolyte shifts is crucial for managing glaucoma patients with renal comorbidities.